Additionally, pre-treatment tumor PD-L1 positivity (TPS ≥ 1%) was associated with favorable recurrence-free survival (RFS) (HR, 0.36, 95% CI, 0.07–1.85) [29]. The gene discussed is CD274; the disease is neoplasm.